Akoya Begin Period Cash Flow vs Dividends Paid Analysis

AKYA Stock

USD 2.31 0.06 2.67%

Akoya Biosciences financial indicator trend analysis is way more than just evaluating Akoya Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Akoya Biosciences is a good investment. Please check the relationship between Akoya Biosciences Begin Period Cash Flow and its Dividends Paid accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akoya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For information on how to trade Akoya Stock refer to our How to Trade Akoya Stock guide.

Begin Period Cash Flow vs Dividends Paid

Begin Period Cash Flow vs Dividends Paid Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Akoya Biosciences Begin Period Cash Flow account and Dividends Paid. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Akoya Biosciences' Begin Period Cash Flow and Dividends Paid is -0.37. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Dividends Paid in the same time period over historical financial statements of Akoya Biosciences, assuming nothing else is changed. The correlation between historical values of Akoya Biosciences' Begin Period Cash Flow and Dividends Paid is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Akoya Biosciences are associated (or correlated) with its Dividends Paid. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Dividends Paid has no effect on the direction of Begin Period Cash Flow i.e., Akoya Biosciences' Begin Period Cash Flow and Dividends Paid go up and down completely randomly.

Correlation Coefficient

-0.37

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Dividends Paid

The total amount of dividends that a company has paid out to its shareholders over a specific period.

Most indicators from Akoya Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Akoya Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akoya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For information on how to trade Akoya Stock refer to our How to Trade Akoya Stock guide.At present, Akoya Biosciences' Tax Provision is projected to decrease significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 63.7 M, whereas Selling General Administrative is forecasted to decline to about 58.6 M.

	2022	2023	2024	2025 (projected)
Interest Expense	4.6M	8.8M	10.1M	10.6M
Depreciation And Amortization	7.1M	8.9M	10.2M	6.0M

Interest Expense Depreciation And Amortization

Akoya Biosciences fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Lease Obligations	Inventory
Total Assets		0.85	0.26	0.94	0.91	-0.71	0.96	0.87	0.85	-0.6	-0.9	0.79	0.98	0.85	0.84	-0.02	0.86	0.99	0.29	-0.45	1.0	0.73	-0.74	-0.27	0.8	0.92
Short Long Term Debt Total	0.85		0.68	0.95	0.68	-0.85	0.69	0.99	0.97	-0.13	-0.94	0.37	0.77	0.96	0.7	-0.26	1.0	0.76	0.43	-0.45	0.89	0.86	-0.69	-0.04	0.92	0.98
Other Current Liab	0.26	0.68		0.57	-0.06	-0.56	0.01	0.68	0.73	0.59	-0.52	-0.34	0.09	0.67	0.01	-0.56	0.67	0.1	0.64	-0.25	0.31	0.63	-0.05	0.58	0.65	0.59
Total Current Liabilities	0.94	0.95	0.57		0.74	-0.78	0.82	0.97	0.97	-0.31	-0.93	0.56	0.86	0.96	0.71	-0.18	0.94	0.87	0.44	-0.46	0.95	0.8	-0.6	-0.01	0.92	0.98
Total Stockholder Equity	0.91	0.68	-0.06	0.74		-0.61	0.94	0.68	0.59	-0.76	-0.77	0.84	0.97	0.66	0.96	0.27	0.69	0.95	-0.1	-0.37	0.9	0.51	-0.87	-0.65	0.63	0.75
Other Liab	-0.71	-0.85	-0.56	-0.78	-0.61		-0.6	-0.82	-0.81	0.02	0.89	-0.28	-0.64	-0.89	-0.7	0.35	-0.85	-0.62	-0.24	0.81	-0.72	-0.81	0.75	0.15	-0.93	-0.81
Net Tangible Assets	0.96	0.69	0.01	0.82	0.94	-0.6		0.72	0.68	-0.76	-0.81	0.9	0.98	0.7	0.86	0.1	0.7	0.99	0.11	-0.44	0.93	0.56	-0.73	-0.41	0.7	0.79
Property Plant And Equipment Net	0.87	0.99	0.68	0.97	0.68	-0.82	0.72		0.97	-0.15	-0.93	0.38	0.78	0.97	0.71	-0.18	0.98	0.78	0.39	-0.42	0.9	0.79	-0.61	-0.02	0.94	0.97
Current Deferred Revenue	0.85	0.97	0.73	0.97	0.59	-0.81	0.68	0.97		-0.1	-0.91	0.38	0.74	0.96	0.58	-0.38	0.97	0.74	0.59	-0.49	0.87	0.9	-0.56	0.15	0.91	0.97
Net Debt	-0.6	-0.13	0.59	-0.31	-0.76	0.02	-0.76	-0.15	-0.1		0.27	-0.94	-0.72	-0.12	-0.62	-0.47	-0.14	-0.73	0.22	0.04	-0.56	-0.07	0.49	0.61	-0.07	-0.28
Retained Earnings	-0.9	-0.94	-0.52	-0.93	-0.77	0.89	-0.81	-0.93	-0.91	0.27		-0.51	-0.85	-0.92	-0.77	0.27	-0.95	-0.83	-0.34	0.59	-0.91	-0.82	0.78	0.17	-0.95	-0.95
Accounts Payable	0.79	0.37	-0.34	0.56	0.84	-0.28	0.9	0.38	0.38	-0.94	-0.51		0.86	0.38	0.68	0.21	0.38	0.87	0.04	-0.29	0.74	0.35	-0.59	-0.45	0.34	0.52
Cash	0.98	0.77	0.09	0.86	0.97	-0.64	0.98	0.78	0.74	-0.72	-0.85	0.86		0.76	0.89	0.09	0.78	1.0	0.15	-0.4	0.97	0.65	-0.81	-0.43	0.72	0.86
Non Current Assets Total	0.85	0.96	0.67	0.96	0.66	-0.89	0.7	0.97	0.96	-0.12	-0.92	0.38	0.76		0.71	-0.21	0.95	0.76	0.38	-0.58	0.88	0.82	-0.61	-0.01	0.96	0.94
Non Currrent Assets Other	0.84	0.7	0.01	0.71	0.96	-0.7	0.86	0.71	0.58	-0.62	-0.77	0.68	0.89	0.71		0.34	0.7	0.87	-0.24	-0.41	0.85	0.47	-0.86	-0.7	0.69	0.72
Other Assets	-0.02	-0.26	-0.56	-0.18	0.27	0.35	0.1	-0.18	-0.38	-0.47	0.27	0.21	0.09	-0.21	0.34		-0.27	0.1	-0.81	0.49	0.0	-0.58	0.02	-0.65	-0.28	-0.24
Long Term Debt	0.86	1.0	0.67	0.94	0.69	-0.85	0.7	0.98	0.97	-0.14	-0.95	0.38	0.78	0.95	0.7	-0.27		0.77	0.45	-0.46	0.89	0.88	-0.71	-0.05	0.91	0.99
Cash And Short Term Investments	0.99	0.76	0.1	0.87	0.95	-0.62	0.99	0.78	0.74	-0.73	-0.83	0.87	1.0	0.76	0.87	0.1	0.77		0.17	-0.4	0.97	0.63	-0.76	-0.39	0.72	0.85
Net Receivables	0.29	0.43	0.64	0.44	-0.1	-0.24	0.11	0.39	0.59	0.22	-0.34	0.04	0.15	0.38	-0.24	-0.81	0.45	0.17		-0.23	0.27	0.68	0.03	0.75	0.32	0.46
Good Will	-0.45	-0.45	-0.25	-0.46	-0.37	0.81	-0.44	-0.42	-0.49	0.04	0.59	-0.29	-0.4	-0.58	-0.41	0.49	-0.46	-0.4	-0.23		-0.42	-0.62	0.52	0.04	-0.65	-0.45
Common Stock Total Equity	1.0	0.89	0.31	0.95	0.9	-0.72	0.93	0.9	0.87	-0.56	-0.91	0.74	0.97	0.88	0.85	0.0	0.89	0.97	0.27	-0.42		0.74	-0.76	-0.27	0.82	0.95
Common Stock Shares Outstanding	0.73	0.86	0.63	0.8	0.51	-0.81	0.56	0.79	0.9	-0.07	-0.82	0.35	0.65	0.82	0.47	-0.58	0.88	0.63	0.68	-0.62	0.74		-0.65	0.14	0.76	0.87
Short Term Investments	-0.74	-0.69	-0.05	-0.6	-0.87	0.75	-0.73	-0.61	-0.56	0.49	0.78	-0.59	-0.81	-0.61	-0.86	0.02	-0.71	-0.76	0.03	0.52	-0.76	-0.65		0.64	-0.62	-0.71
Non Current Liabilities Total	-0.27	-0.04	0.58	-0.01	-0.65	0.15	-0.41	-0.02	0.15	0.61	0.17	-0.45	-0.43	-0.01	-0.7	-0.65	-0.05	-0.39	0.75	0.04	-0.27	0.14	0.64		-0.03	-0.07
Capital Lease Obligations	0.8	0.92	0.65	0.92	0.63	-0.93	0.7	0.94	0.91	-0.07	-0.95	0.34	0.72	0.96	0.69	-0.28	0.91	0.72	0.32	-0.65	0.82	0.76	-0.62	-0.03		0.9
Inventory	0.92	0.98	0.59	0.98	0.75	-0.81	0.79	0.97	0.97	-0.28	-0.95	0.52	0.86	0.94	0.72	-0.24	0.99	0.85	0.46	-0.45	0.95	0.87	-0.71	-0.07	0.9

Click cells to compare fundamentals

Akoya Biosciences Account Relationship Matchups

Akoya Biosciences fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	77.7M	190.9M	176.0M	180.4M	207.4M	157.2M
Short Long Term Debt Total	35.0M	32.7M	75.8M	85.7M	98.6M	55.9M
Other Current Liab	7.0M	(272K)	12.9M	13.4M	15.4M	9.2M
Total Current Liabilities	17.2M	27.7M	37.1M	35.3M	40.6M	30.4M
Total Stockholder Equity	18.6M	121.4M	58.6M	53.8M	61.8M	48.9M
Property Plant And Equipment Net	5.5M	7.5M	22.4M	20.7M	23.8M	13.4M
Current Deferred Revenue	3.8M	4.5M	6.3M	6.7M	7.7M	5.6M
Net Debt	18.0M	(80.6M)	1.6M	2.6M	2.3M	2.4M
Retained Earnings	(52.3M)	(96.1M)	(166.7M)	(230.1M)	(207.1M)	(196.7M)
Accounts Payable	5.1M	23.2M	10.6M	11.8M	13.5M	12.9M
Cash	17.0M	113.1M	74.2M	83.1M	95.6M	65.8M
Non Current Assets Total	49.0M	50.1M	63.8M	58.6M	67.4M	59.4M
Non Currrent Assets Other	2.5M	3.2M	3.1M	2.2M	2.6M	2.7M
Other Assets	2.5M	3.2M	3.1M	1.0	0.9	0.86
Long Term Debt	33.5M	32.5M	63.3M	75.3M	86.5M	50.4M
Cash And Short Term Investments	17.0M	113.1M	81.2M	83.1M	95.6M	69.5M
Net Receivables	6.5M	9.4M	9.7M	17.0M	19.5M	12.3M
Liabilities And Stockholders Equity	77.7M	190.9M	176.0M	180.4M	207.4M	157.2M
Non Current Liabilities Total	41.9M	41.9M	80.4M	91.3M	104.9M	77.9M
Capital Lease Obligations	474K	469K	12.5M	10.5M	12.0M	12.6M
Inventory	4.3M	9.0M	14.5M	17.9M	20.6M	10.9M
Other Current Assets	957K	9.3M	6.8M	3.8M	4.4M	5.0M
Other Stockholder Equity	490K	217.5M	225.3M	283.8M	326.4M	342.7M
Total Liab	59.1M	69.6M	117.5M	126.6M	145.6M	108.3M
Net Invested Capital	(17.8M)	32.5M	121.9M	129.0M	148.4M	155.8M
Property Plant And Equipment Gross	5.5M	11.6M	22.4M	30.3M	34.9M	36.6M
Total Current Assets	28.7M	140.8M	112.2M	121.8M	140.1M	97.8M
Non Current Liabilities Other	7.0M	9.4M	17.0M	5.8M	6.6M	10.4M
Net Working Capital	11.5M	113.1M	75.1M	86.4M	99.4M	67.3M
Short Term Debt	1.2M	272K	7.3M	3.4M	4.0M	2.7M
Intangible Assets	22.7M	21.2M	20.0M	17.4M	15.7M	16.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CSX	CSX Corporation
ETON	Eton Pharmaceuticals
ALLT	Allot Communications

When determining whether Akoya Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akoya Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akoya Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akoya Biosciences Stock:

How To Invest In Akoya

Details

Is Akoya Stock a good investment?

Details

What is Akoya Biosciences' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akoya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For information on how to trade Akoya Stock refer to our How to Trade Akoya Stock guide.

You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akoya Biosciences. If investors know Akoya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akoya Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.16)

Revenue Per Share

1.756

Quarterly Revenue Growth

(0.25)

Return On Assets

(0.18)

Return On Equity

(1.53)

The market value of Akoya Biosciences is measured differently than its book value, which is the value of Akoya that is recorded on the company's balance sheet. Investors also form their own opinion of Akoya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Akoya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akoya Biosciences' market value can be influenced by many factors that don't directly affect Akoya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Akoya Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akoya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akoya Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Akoya Begin Period Cash Flow vs Dividends Paid Analysis

Begin Period Cash Flow vs Dividends Paid

Begin Period Cash Flow vs Dividends Paid Correlation Analysis

Correlation Coefficient

Begin Period Cash Flow

Dividends Paid

Akoya Biosciences fundamental ratios Correlations

Akoya Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Akoya Biosciences fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock Total Equity	+ 1.0	Total Assets
Long Term Debt	+ 1.0	Short Long Term Debt Total
Cash And Short Term Investments	+ 1.0	Cash
Cash And Short Term Investments	+ 0.99	Total Assets
Property Plant And Equipment Net	+ 0.99	Short Long Term Debt Total
Cash And Short Term Investments	+ 0.99	Net Tangible Assets

Inventory	- 0.95	Retained Earnings
Capital Lease Obligations	- 0.95	Retained Earnings
Long Term Debt	- 0.95	Retained Earnings
Accounts Payable	- 0.94	Net Debt
Retained Earnings	- 0.94	Short Long Term Debt Total
Retained Earnings	- 0.93	Property Plant And Equipment Net